A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT06196775 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
36
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Harbin Medical University